SLG
IONS icon

Stanley-Laman Group’s Ionis Pharmaceuticals IONS Stock Holding History

Stanley-Laman Group’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.95M Buy
39,306
+2,794
+8% +$221K 0.36% 107
2025
Q4 		$2.89M Buy
36,512
+738
+2% +$55.6K 0.37% 104
2025
Q3 		$2.34M Buy
+35,774
New +$1.75M 0.33% 113

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Stanley-Laman Group's IONS Position: Q1 2026 in Review

Stanley-Laman Group increased its Ionis Pharmaceuticals (IONS) stake by 7.7% in Q1 2026, buying an estimated $221K and bringing the position to 39,306 shares worth $2.95M. The position accounts for 0.36% of the portfolio, ranked #107.

Stanley-Laman Group first reported a position in IONS in Q3 2025 and has held it in 3 quarters since. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • Stanley-Laman Group held 39,306 shares of Ionis Pharmaceuticals worth $2.95M as of Q1 2026.
  • Stanley-Laman Group bought 2,794 Ionis Pharmaceuticals shares in Q1 2026, an estimated $221K.
  • Ionis Pharmaceuticals made up 0.36% of Stanley-Laman Group's portfolio in Q1 2026, its #107 holding.
  • Stanley-Laman Group first reported a position in Ionis Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Stanley-Laman Group's 13F filing for Q1 2026, filed 16 Apr 2026.